Lindbrook Capital LLC Sells 352 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Lindbrook Capital LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,809 shares of the medical research company’s stock after selling 352 shares during the period. Lindbrook Capital LLC’s holdings in Thermo Fisher Scientific were worth $4,830,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Empowered Funds LLC grew its holdings in Thermo Fisher Scientific by 53.3% in the first quarter. Empowered Funds LLC now owns 7,704 shares of the medical research company’s stock worth $4,478,000 after purchasing an additional 2,677 shares during the period. WealthPLAN Partners LLC boosted its holdings in Thermo Fisher Scientific by 15.7% in the 1st quarter. WealthPLAN Partners LLC now owns 3,867 shares of the medical research company’s stock worth $2,247,000 after buying an additional 524 shares during the period. Atomi Financial Group Inc. grew its holdings in Thermo Fisher Scientific by 29.2% during the 1st quarter. Atomi Financial Group Inc. now owns 1,404 shares of the medical research company’s stock valued at $816,000 after buying an additional 317 shares in the last quarter. Keudell Morrison Wealth Management increased its holdings in shares of Thermo Fisher Scientific by 57.2% in the first quarter. Keudell Morrison Wealth Management now owns 1,006 shares of the medical research company’s stock worth $585,000 after purchasing an additional 366 shares during the last quarter. Finally, Nixon Peabody Trust Co. raised its stake in Thermo Fisher Scientific by 6.3% during the first quarter. Nixon Peabody Trust Co. now owns 33,538 shares of the medical research company’s stock valued at $19,493,000 after purchasing an additional 1,996 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,150 shares of company stock worth $15,676,125. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $551.74 on Friday. The stock has a market cap of $211.04 billion, a price-to-earnings ratio of 34.59, a PEG ratio of 3.70 and a beta of 0.79. Thermo Fisher Scientific Inc. has a fifty-two week low of $437.26 and a fifty-two week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The business has a 50 day moving average price of $593.95 and a 200 day moving average price of $583.63.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the firm posted $5.69 EPS. The company’s revenue was up .2% on a year-over-year basis. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Bank of America boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Stephens initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.